Stay updated with breaking news from Eric Jonasch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Vial introduces a new member joining their Oncology CRO Advisory Board. Eric Jonasch, MD, is a Genitourinary Medical Oncology Professor and...
Belzutifan is an important step forward in the treatment of kidney cancer and other neoplasms associated with von Hippel-Lindau disease.
The hypoxia-inducible factor 2α inhibitor belzutifan is active in renal cell carcinoma associated with von Hippel-Lindau (VHL) disease.
Patients with von Hippel-Lindau face a high risk of renal cell carcinoma and other cancers, which often require multiple surgeries. A new drug may change the course of the disease.
Belzutifan might serve as an alternative for or a complement to surgery Belzutifan (MK-6482), a novel oral agent that targets germline pathogenic variants in the von Hippel-Lindau (VHL) gene that gives rise to VHL disease, demonstrated robust clinical activity and a very mild adverse event (AE) profile in VHL patients with renal cell carcinoma, a